Cardiovascular Systems enrols first subject in ECLIPSE coronary clinical trial

123
Cardiovascular Systems Diamondback 360

Cardiovascular Systems and the Cardiovascular Research Foundation (CRF) have announced that the first subject has been enrolled in the ECLIPSE clinical trial. The subject was treated by Richard Shlofmitz, interventional cardiologist and the Director of the Department of Cardiology at St Francis Hospital, Roslyn, USA, Shlofmitz also treated subjects in Cardiovascular Systems’s ORBIT II and COAST clinical studies.

“Severely calcified coronary lesions have continued to grow in complexity while treating coronary artery disease,” Shlofmitz says. “The Diamondback 360 coronary orbital atherectomy system provides a novel treatment option for these patients compared to conventional angioplasty. Definitive data from the ECLIPSE clinical trial will guide my treatment approach for these difficult-to-treat patients.”

ECLIPSE is a prospective, multicentre, randomised clinical trial of approximately 2,000 subjects with severely calcified coronary lesions in the USA. Half the participants will receive orbital atherectomy prior to drug-eluting stent implantation, while the other half will receive conventional angioplasty, including specialty balloons, followed by drug-eluting stent implantation. The trial is powered to demonstrate differences in the primary endpoints of post-procedural minimal cross-sectional area (assessed by intravascular imaging in a subset of up to 400 patients) as well as in the clinical outcome of target vessel failure at one year. ECLIPSE will also evaluate key health economic outcomes.

“Many of us feel that coronary atherectomy is underutilised, particularly given the increasing complexity of lesions and patients seen in current-day interventional practice,” says Ajay Kirtane, the director of the Cardiac Catheterization Laboratories at New York-Presbyterian/Columbia University Irving Medical Center, and one of the principal investigators of the trial. “ECLIPSE is the largest randomised clinical trial to date expressly designed to assess the utility of adjunctive coronary atherectomy for calcific coronary artery disease.”

Philippe Généreux, co-principal investigator of the trial, interventional cardiologist at Morristown Medical Center, Morristown, USA, and the director of the Angiographic Core Laboratory at the CRF Clinical Trials Center, “Coronary calcification has been shown to increase procedural difficulty and adverse events following conventional percutaneous coronary intervention. The use of orbital atherectomy has the ability to significantly modify lesion morphology, enabling successful stent delivery to help optimize stent expansion and apposition. This supports why we are randomizing to conventional angioplasty, toward the goal of ultimately improving percutaneous coronary intervention outcomes. The value of this trial is that it will inform physicians regarding the most effective treatment protocols and strategies for treating patients with calcific coronary artery disease.”

Cardiovascular Systems’s Diamondback 360 coronary orbital atherectomy system is the first and only atherectomy device approved to specifically treat severely calcified coronary arteries. Since US Food and Drug Administration approval in October 2013, over 25,000 devices have been used to treat patients with coronary artery disease.